Tuesday, November 29, 2011
Shire has entered into an agreement with Shionogi & Co. of Japan to co-develop and co-commercialize certain of Shire’s Attention Deficit Hyperactivity Disorder (ADHD) medicines in Japan. Shionogi will pay a one time fee and share costs with Shire in exchange for rights to jointly co-develop and co-commercialize the products upon approval for the Japanese market. Specific terms of the agreement are not being disclosed.
South Texas Accelerated Research Therapeutics (START), a US-based group that claims to run the world’s largest co-ordinated network of phase I clinical trials in oncology, has opened a phase I research facility in China at Fudan University Shanghai Cancer Centre, the city’s largest cancer hospital, according to PharmaTimes.